Yes, estrogen blockers increase testosterone in men. They work by disrupting the hormonal feedback loop that normally keeps testosterone production in check. In clinical trials, men with low testosterone who took clomiphene citrate (a common estrogen blocker) saw their total testosterone rise by roughly 260 ng/dL on average. The size of the increase depends on which type of estrogen blocker is used and how the individual’s body responds.
How Estrogen Controls Testosterone Production
Your body regulates testosterone through a communication chain between three structures: the hypothalamus (in the brain), the pituitary gland (just below it), and the testes. The hypothalamus sends a signal to the pituitary, which then releases two hormones, LH and FSH, that tell the testes to produce testosterone and sperm. This is sometimes called the HPG axis.
Here’s the part most people don’t realize: estrogen is the primary brake on this system in men, not testosterone itself. Your body naturally converts some testosterone into estradiol (the main form of estrogen) using an enzyme called aromatase. That estradiol travels back to the hypothalamus and pituitary and tells them to slow down. Studies on men who genetically lack the ability to make this conversion confirm the relationship directly: without estradiol feeding back to the brain, LH secretion rises sharply. The same pattern appears in animals immunized against estradiol. Remove the estrogen signal, and the brain ramps up its hormonal output.
Estrogen blockers exploit this mechanism. By interfering with estrogen’s ability to deliver its “slow down” message, they trick the brain into thinking hormone levels are low, prompting it to send stronger signals to the testes.
Two Types of Estrogen Blockers
There are two main categories, and they work differently.
Selective estrogen receptor modulators (SERMs) like clomiphene and tamoxifen block estrogen receptors in the hypothalamus and pituitary. Estrogen is still being produced normally throughout the body, but the brain can’t “see” it. The pituitary responds by releasing more LH and FSH, which drives the testes to make more testosterone. Because estrogen is still present in the bloodstream, estradiol levels actually rise alongside testosterone. This preserves the protective roles estrogen plays in bone health, brain function, and sexual desire.
Aromatase inhibitors (AIs) like anastrozole and letrozole take a different approach. Instead of blocking the receptor, they block the enzyme that converts testosterone into estrogen in the first place. This reduces circulating estradiol levels, which also lifts the brake on the pituitary. The result is higher testosterone and lower estrogen simultaneously.
How Much Testosterone Increases
A head-to-head trial published in The Journal of Sexual Medicine compared clomiphene citrate to anastrozole in men with low testosterone over 12 weeks. Both raised testosterone significantly, but clomiphene produced a larger absolute increase: men on clomiphene reached average levels of 571 ng/dL compared to 408 ng/dL in the anastrozole group. A meta-analysis of clomiphene studies in men with hypogonadism found an average total testosterone increase of about 260 ng/dL, though individual results varied widely.
Anastrozole, while producing a smaller testosterone bump, created a much larger shift in the testosterone-to-estradiol ratio. That ratio matters for certain conditions, particularly male infertility. A ratio below roughly 10:1 is considered low based on large cohort data, and aromatase inhibitors are particularly effective at correcting it.
Why This Matters for Fertility
The biggest practical advantage of estrogen blockers over standard testosterone replacement therapy is what happens to sperm production. Injecting or applying testosterone externally floods the body with the hormone, which paradoxically shuts down the brain’s signals to the testes. LH and FSH drop, and sperm production can grind to a halt. Many men on testosterone therapy become temporarily infertile, and their testes may shrink.
Estrogen blockers do the opposite. By boosting LH and FSH, they stimulate the testes to produce both testosterone and sperm simultaneously. Tamoxifen, for example, increases testosterone synthesis while actively supporting sperm production. In one study, anastrozole (at an average dose of about 3 mg per week) improved semen quality in 46% of infertile men treated, and 29% achieved normal sperm parameters. It also enabled nearly a third of previously ineligible men to qualify for intrauterine insemination. Combined protocols using estrogen blockers alongside other fertility medications restored sperm production in over 95% of men with severely low or absent sperm counts.
That said, men who started with zero sperm production (azoospermia) rarely responded to anastrozole alone. Only 1 out of 17 men with azoospermia saw improvement in that study.
The Risk of Suppressing Estrogen Too Low
Men need estrogen. It plays a direct role in bone density, brain function, and sexual health. Aromatase inhibitors carry a specific risk that SERMs generally don’t: they can push estradiol levels dangerously low.
When estradiol drops below about 5 ng/dL in men, libido decreases noticeably, even if testosterone levels are adequate. One study found that when men with low testosterone were treated with letrozole (a potent aromatase inhibitor), sexual desire dropped, likely because estradiol was suppressed too aggressively. In men with testosterone under 300 ng/dL, sexual drive was markedly higher when estradiol remained above that 5 ng/dL floor.
Bone health is another concern. While most short-term studies of aromatase inhibitors in adult men haven’t shown major bone problems, one study found decreased spine bone mineral density after a year of anastrozole use in older men. In adolescent boys treated for delayed puberty, vertebral deformities were observed. Adding anastrozole to testosterone therapy also interfered with improvements in verbal memory in one trial, suggesting estrogen plays a role in certain cognitive functions that shouldn’t be casually eliminated.
SERMs vs. Aromatase Inhibitors: Which Is Better
For raising testosterone alone, clomiphene (a SERM) produces higher absolute levels and preserves estrogen’s protective functions throughout the body. It’s the more commonly used option for men with low testosterone who want to avoid injectable testosterone, particularly if fertility is a concern.
Aromatase inhibitors are typically reserved for men who have an abnormally high testosterone-to-estradiol ratio or symptoms specifically linked to excess estrogen, such as breast tissue growth. They’re more targeted but carry more risk if estradiol drops too far.
Neither class of medication has well-established long-term safety data in men. Both are used off-label for male hormonal issues, as they were originally developed for conditions like breast cancer in women. Short and medium-term studies show generally manageable side effect profiles, but routine long-term use is not formally recommended based on current evidence. Bone health monitoring is particularly important for anyone on an aromatase inhibitor for an extended period.